Recently, elevated tumor nitric oxide synthase 2 (NOS2) and COX2 coexpression has shown strong predictive power, in which their elevated expression correlates with reduced survival in ER− but not ER+ breast cancer (2). Here, NOS2 is linked to breast carcinoma.